A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

Trial Profile

A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 May 2018

At a glance

  • Drugs Pazopanib (Primary) ; Gemcitabine
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 May 2018 Planned End Date changed from 1 Dec 2018 to 1 Oct 2018.
    • 01 May 2018 Planned primary completion date changed from 1 Apr 2017 to 1 Jun 2018.
    • 06 Jun 2017 Results assessing the effect of adding pazopanib to gemcitabine in patients with recurrent, advanced ovarian cancer, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top